Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme

Background The natural compound n-butylidenephthalide (BP) can pass through the blood–brain barrier to inhibit the growth of glioblastoma multiforme tumors. However, BP has an unstable structure that reduces its antitumor activity and half-life in vivo. Objective The aim of this study is to design a drug delivery system to encapsulate BP to enhance its efficacy by improving its protection and delivery. Methods To protect its structural stability against protein-rich and peroxide solutions, BP was encapsulated into a lipo-PEG-PEI complex (LPPC). Then, the cytotoxicity of BP/LPPC following preincubation in protein-rich, acid/alkaline, and peroxide solutions was analyzed by MTT. Cell uptake of BP/LPPC was also measured by confocal microscopy. The therapeutic effects of BP/LPPC were analyzed in xenograft mice following intratumoral and intravenous injections. Results When BP was encapsulated in LPPC, its cytotoxicity was maintained following preincubation in protein-rich, acid/alkaline, and peroxide solutions. The cytotoxic activity of encapsulated BP was higher than that of free BP (~4.5- to 8.5-fold). This increased cytotoxic activity of BP/LPPC is attributable to its rapid transport across the cell membrane. In an animal study, a subcutaneously xenografted glioblastoma multiforme mouse that was treated with BP by intratumoral and intravenous administration showed inhibited tumor growth. The same dose of BP/LPPC was significantly more effective in terms of tumor inhibition. Conclusion LPPC encapsulation technology is able to protect BP’s structural stability and enhance its antitumor effects, thus providing a better tool for use in cancer therapy.

[1]  P. Marsden,et al.  Expression in Cardiac Myocytes In Vitro and In Vivo p 38 MAP Kinase Signaling Cascade Regulates Cyclooxygenase-2 − MAP Kinase Kinase 6 , 2003 .

[2]  H. Harn,et al.  Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability , 2014, Tumor Biology.

[3]  郑俊海,et al.  科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会 , 2014 .

[4]  Ying Huang,et al.  Effects of natural phytochemicals in Angelica sinensis (Danggui) on Nrf2‐mediated gene expression of phase II drug metabolizing enzymes and anti‐inflammation , 2013, Biopharmaceutics & drug disposition.

[5]  H. Harn,et al.  Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  Chia-Hung Chen,et al.  A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[7]  H. Harn,et al.  Induction of Apoptosis Coupled to Endoplasmic Reticulum Stress in Human Prostate Cancer Cells by n-butylidenephthalide , 2012, PloS one.

[8]  Chia-Hung Chen,et al.  Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch , 2012, International journal of nanomedicine.

[9]  M. von Knebel Doeberitz,et al.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.

[10]  Fu-Rong Chen,et al.  A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene Glycol: A nondisplaceable property , 2011, Biotechnology and bioengineering.

[11]  H. Harn,et al.  Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas , 2011, Annals of Surgical Oncology.

[12]  H. Harn,et al.  Overexpression of the orphan receptor Nur77 and its translocation induced by PCH4 may inhibit malignant glioma cell growth and induce cell apoptosis , 2011, Journal of surgical oncology.

[13]  D. Charnock-Jones,et al.  The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo , 2011, Angiogenesis.

[14]  Shinn-Zong Lin,et al.  Lipopolysaccharide-stimulated activation of murine DC2.4 cells is attenuated by n-butylidenephthalide through suppression of the NF-κB pathway , 2011, Biotechnology Letters.

[15]  H. Harn,et al.  Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma , 2012, Investigational New Drugs.

[16]  José Weber Vieira de Faria,et al.  Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. , 2010, Arquivos de neuro-psiquiatria.

[17]  Sarah Zohar,et al.  Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. , 2010, Neuro-oncology.

[18]  P. Opanasopit,et al.  Incorporation methods for cholic acid chitosan-g-mPEG self-assembly micellar system containing camptothecin. , 2009, Colloids and surfaces. B, Biointerfaces.

[19]  Min-tze Wu,et al.  n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2α and telomerase activity , 2009, Acta Pharmacologica Sinica.

[20]  H. Harn,et al.  The Induction of Orphan Nuclear Receptor Nur77 Expression by n-Butylenephthalide as Pharmaceuticals on Hepatocellular Carcinoma Cell Therapy , 2008, Molecular Pharmacology.

[21]  H. Harn,et al.  Orphan nuclear receptor, Nurr‐77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor , 2008, Journal of neurochemistry.

[22]  G. Lin,et al.  Pharmacokinetics and Metabolism of Ligustilide, a Major Bioactive Component in Rhizoma Chuanxiong, in the Rat , 2008, Drug Metabolism and Disposition.

[23]  P. Opanasopit,et al.  Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  H. Harn,et al.  The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo3 , 2006, Journal of neurochemistry.

[25]  J. Bolton,et al.  Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. , 2006, Journal of natural products.

[26]  Teruo Okano,et al.  Influence of serum and albumins from different species on stability of camptothecin-loaded micelles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[27]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[29]  I. Nabiev,et al.  Interactions of lactone, carboxylate and self‐aggregated forms of camptothecin with human and bovine serum albumins , 1997, FEBS letters.

[30]  T. Burke,et al.  Differential interactions of camptothecin lactone and carboxylate forms with human blood components. , 1994, Biochemistry.

[31]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.